Eversept Partners’s Crescent Biopharma CBIO Stock Holding History

Eversept Partners’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,006	Closed	-$305K	–	69
2022 Q4	$305K	Hold	1,006	–	–	0.03%	63
2022 Q3	$55.5K	Hold	1,006	–	–	﹤0.01%	69
2022 Q2	$60.1K	Hold	1,006	–	–	﹤0.01%	77
2022 Q1	$115K	Buy	1,006 +6	+0.6%	+$704	0.01%	85
2021 Q4	$144K	Buy	+1,000	New	+$181K	0.01%	107

Other funds holding CBIO

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Eversept Partners's CBIO Position: Q1 2023 in Review

Eversept Partners sold out of Crescent Biopharma (CBIO) in Q1 2023, closing a stake of 1,006 shares — an estimated $305K sold.

Eversept Partners first reported a position in CBIO in Q4 2021 and held it in 5 quarters. The position peaked at $305K in Q4 2022. 54 funds tracked by Wall St. Rank hold CBIO as of Q1 2023.

Eversept Partners reported no remaining Crescent Biopharma position as of Q1 2023 after selling out during the quarter.
Eversept Partners sold 1,006 Crescent Biopharma shares in Q1 2023, an estimated $305K.
Eversept Partners first reported a position in Crescent Biopharma in Q4 2021 and held it in 5 quarters.
Eversept Partners's Crescent Biopharma position peaked at $305K in Q4 2022.
54 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2023.

Based on Eversept Partners's 13F filing for Q1 2023, filed 15 May 2023.